28456850|t|Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial
28456850|a|Obesity is a well-known risk factor for the development of cancer, but its influence on the course of disease is still controversial. We investigated the influence of body mass index (BMI) on overall survival (OS) in 502 patients with indolent non-Hodgkin's lymphoma or mantle cell lymphoma in a subgroup analysis of the StiL (Study Group Indolent Lymphomas) NHL1 trial. We defined a cut-off of 22.55 kg/m(2) by ROC calculation and Youden Index analysis and stratified patients into " low BMI " and " high BMI ". Five- year OS was significantly longer in the high BMI group (82.2%) when compared to that of the low BMI group (66.2%) (HR 0.597; 95% CI 0.370-0.963; p = 0.034). BMI was also an independent prognostic factor for OS in multivariate analysis (HR 0.541; 95% CI 0.332-0.883; p = 0.014). Of note, patients had a significantly lower BMI in the presence than patients in the absence of B-symptoms (p = 0.025). BMI significantly impacts on OS in indolent non-Hodgkin's lymphoma and mantle cell lymphoma, which may be influenced by the effect of B-symptoms on BMI.
28456850	0	9	Influence	T077	C4054723
28456850	13	28	body mass index	T201	C1305855
28456850	32	40	survival	T052	C0038952
28456850	44	52	indolent	T191	C1334170
28456850	57	78	mantle cell lymphomas	T191	C0334634
28456850	80	88	analysis	T062	C0936012
28456850	96	100	StiL	T098	C2348561
28456850	101	105	NHL1	T191	C0024305
28456850	106	111	trial	T062	C0681815
28456850	112	119	Obesity	T047	C0028754
28456850	136	147	risk factor	T033	C0035648
28456850	171	177	cancer	T191	C0006826
28456850	187	196	influence	T077	C4054723
28456850	214	221	disease	T047	C0012634
28456850	249	261	investigated	T169	C1292732
28456850	266	275	influence	T077	C4054723
28456850	279	294	body mass index	T201	C1305855
28456850	296	299	BMI	T201	C1305855
28456850	304	320	overall survival	T081	C4086681
28456850	322	324	OS	T081	C4086681
28456850	333	341	patients	T101	C0030705
28456850	347	378	indolent non-Hodgkin's lymphoma	T191	C1334170
28456850	382	402	mantle cell lymphoma	T191	C0334634
28456850	408	416	subgroup	T185	C1515021
28456850	417	425	analysis	T062	C0936012
28456850	433	437	StiL	T098	C2348561
28456850	439	450	Study Group	T098	C2348561
28456850	451	469	Indolent Lymphomas	T191	C1334170
28456850	471	475	NHL1	T191	C0024305
28456850	476	481	trial	T062	C0681815
28456850	524	527	ROC	T081	C0035787
28456850	528	539	calculation	T052	C1441506
28456850	544	556	Youden Index	T170	C0918012
28456850	557	565	analysis	T062	C0936012
28456850	570	580	stratified	T080	C0205363
28456850	581	589	patients	T101	C0030705
28456850	597	604	low BMI	T033	C0231255
28456850	613	621	high BMI	T033	C0231254
28456850	631	635	year	T079	C0439234
28456850	636	638	OS	T081	C4086681
28456850	643	656	significantly	T078	C0750502
28456850	657	663	longer	T080	C0205166
28456850	671	679	high BMI	T033	C0231254
28456850	680	685	group	T098	C1257890
28456850	699	707	compared	T052	C1707455
28456850	723	730	low BMI	T033	C0231255
28456850	731	736	group	T098	C1257890
28456850	746	748	HR	T081	C2985465
28456850	760	762	CI	T081	C0009667
28456850	776	777	p	T081	C1709380
28456850	788	791	BMI	T201	C1305855
28456850	816	833	prognostic factor	T201	C1514474
28456850	838	840	OS	T081	C4086681
28456850	844	865	multivariate analysis	T081	C0026777
28456850	867	869	HR	T081	C2985465
28456850	881	883	CI	T081	C0009667
28456850	897	898	p	T081	C1709380
28456850	918	926	patients	T101	C0030705
28456850	933	946	significantly	T078	C0750502
28456850	947	956	lower BMI	T033	C0231255
28456850	978	986	patients	T101	C0030705
28456850	1005	1015	B-symptoms	T033	C1706867
28456850	1017	1018	p	T081	C1709380
28456850	1029	1032	BMI	T201	C1305855
28456850	1033	1046	significantly	T078	C0750502
28456850	1047	1054	impacts	T080	C4049986
28456850	1058	1060	OS	T081	C4086681
28456850	1064	1095	indolent non-Hodgkin's lymphoma	T191	C1334170
28456850	1100	1120	mantle cell lymphoma	T191	C0334634
28456850	1135	1145	influenced	T077	C4054723
28456850	1153	1159	effect	T080	C1280500
28456850	1163	1173	B-symptoms	T033	C1706867
28456850	1177	1180	BMI	T201	C1305855